ASCO GI 2023 | The future of immunotherapy in MMR proficient colorectal cancer

Hazel Lote, PhD, Institute of Cancer Research, Sutton, UK, comments on the advances in immunotherapy for mismatch repair (MMR) proficient colorectal cancer, which historically have not responded well to immunotherapy. Multiple studies are assessing combination therapies with other immune checkpoint inhibitors or targeted therapies such as VEGF inhibitors. Patients with liver metastases have additionally been reported to have outcomes different to patients with other metastases. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.